Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Serina Therapeutics (SER) EBITDA (2018 - 2025)

Serina Therapeutics (SER) has disclosed EBITDA for 8 consecutive years, with -$6.2 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 11.86% to -$6.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$22.2 million through Dec 2025, down 114.71% year-over-year, with the annual reading at -$24.0 million for FY2025, 40.91% down from the prior year.
  • EBITDA hit -$6.2 million in Q4 2025 for Serina Therapeutics, down from -$4.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $1.4 million in Q3 2024 to a low of -$6.2 million in Q4 2025.
  • Historically, EBITDA has averaged -$2.5 million across 5 years, with a median of -$2.0 million in 2021.
  • Biggest YoY gain for EBITDA was 194.53% in 2024; the steepest drop was 2402.49% in 2024.
  • Year by year, EBITDA stood at -$1.9 million in 2021, then increased by 4.55% to -$1.8 million in 2022, then soared by 113.52% to $241000.0 in 2023, then crashed by 2402.49% to -$5.5 million in 2024, then dropped by 11.86% to -$6.2 million in 2025.
  • Business Quant data shows EBITDA for SER at -$6.2 million in Q4 2025, -$4.6 million in Q3 2025, and -$5.6 million in Q2 2025.